{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:51:08Z","timestamp":1777366268868,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,17]]},"DOI":"10.1038\/s41416-021-01448-0","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T08:03:32Z","timestamp":1622189012000},"page":"528-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas"],"prefix":"10.1038","volume":"125","author":[{"given":"Brian","family":"Schulte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Milhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Monga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-0771","authenticated-orcid":false,"given":"Angela C.","family":"Hirbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Oppelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Charlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Helenowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Abbinanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasima","family":"Cehic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-3519","authenticated-orcid":false,"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"1448_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark, M. A., Fisher, C., Judson, I. & Meirion Thomas, J. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701\u2013711 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1448_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1448_CR3","doi-asserted-by":"crossref","unstructured":"Benjamin, R. S. & George, S. Soft Tissue Sarcoma Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 16, 536\u2013563 (2018).","DOI":"10.6004\/jnccn.2018.0025"},{"key":"1448_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Sch\u00f6ffski, P., Blay, J. Y. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15, 415\u2013423 (2014).","journal-title":"Lancet Oncol."},{"key":"1448_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"M Van Glabbeke","year":"1999","unstructured":"Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens\u2013a European Organization for Research and Treatment of Cancer Soft Tissue and Bone. J. Clin. Oncol. 17, 150\u2013157 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1448_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127\u20131134 (2004).","journal-title":"Lancet"},{"key":"1448_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D., Von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786\u2013793 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1448_CR8","doi-asserted-by":"publisher","first-page":"asonc02906q0015","DOI":"10.1053\/sonc.2002.37263","volume":"29","author":"J Folkman","year":"2002","unstructured":"Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, asonc02906q0015 (2002).","journal-title":"Semin. Oncol."},{"key":"1448_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H.-P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669\u2013676 (2003).","journal-title":"Nat. Med."},{"key":"1448_CR10","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA Van Der Graaf","year":"2012","unstructured":"Van Der Graaf, W. T. A., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879\u20131886 (2012).","journal-title":"Lancet"},{"key":"1448_CR11","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.20.00714","volume":"38","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald, V., Karch, A., Schuler, M., Sch\u00f6ffski, P., Kopp, H.-G., Bauer, S. et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German Intergroup Study. J. Clin. Oncol. 38, 3555\u20133564 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1448_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","volume":"7","author":"H-J Schmoll","year":"2021","unstructured":"Schmoll, H.-J., Lindner, L. H., Reichardt, P., Hei\u00dfner, K., Kopp, H.-G., Kessler, T. et al. Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and\/or ifosfamide-refractory soft tissue sarcoma. JAMA Oncol. 7, 255 (2021).","journal-title":"JAMA Oncol."},{"key":"1448_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00000421-200008000-00009","volume":"23","author":"DS Miller","year":"2000","unstructured":"Miller, D. S., Blessing, J. A., Kilgore, L. C., Mannel, R. & Van Le, L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas. Am. J. Clin. Oncol. 23, 355\u2013357 (2000).","journal-title":"Am. J. Clin. Oncol."},{"key":"1448_CR14","doi-asserted-by":"crossref","unstructured":"Reichardt, P., Oechsle, K., Pink, D., Bokemeyer, C., Schneller, F., Issels, R. et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest. New Drugs 21, 481\u2013486 (2003).","DOI":"10.1023\/A:1026263604863"},{"key":"1448_CR15","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1200\/JCO.2001.19.15.3463","volume":"19","author":"RL Saylors","year":"2001","unstructured":"Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L. et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II Study. J. Clin. Oncol. 19, 3463\u20133469 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1448_CR16","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-11-0078","volume":"17","author":"S Kumar","year":"2011","unstructured":"Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B., Zhang, L., Xu, P. et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656\u20135667 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1448_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/1535-7163.MCT-09-0960","volume":"9","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto, K., Man, S., Xu, P., Cruz-Munoz, W., Tang, T., Kumar, R. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996\u20131006 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"1448_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/bjc.2015.257","volume":"113","author":"BM Kerklaan","year":"2015","unstructured":"Kerklaan, B. M., Lolkema, M. P. J., Devriese, L. A., Voest, E. E., Nol-Boekel, A., Mergui-Roelvink, M. et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Br. J. Cancer 113, 706\u2013715 (2015).","journal-title":"Br. J. Cancer"},{"key":"1448_CR19","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629\u20131637 (2016).","journal-title":"Lancet"},{"key":"1448_CR20","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2015.65.5381","volume":"34","author":"JP Lagmay","year":"2016","unstructured":"Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through children\u2019s cancer group, Pediatric Oncology Group, and Children\u2019s Oncology Group: Learning From the Past to Move Forward. J. Clin. Oncol. 34, 3031\u20133038 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1448_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120\u2013133 (2019).","journal-title":"Lancet Oncol."},{"key":"1448_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446\u2013455 (2020).","journal-title":"Lancet Oncol."},{"key":"1448_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","volume":"109","author":"S Smeland","year":"2019","unstructured":"Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer 109, 36\u201350 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1448_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","volume":"115","author":"L Mirabello","year":"2009","unstructured":"Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115, 1531\u20131543 (2009).","journal-title":"Cancer"},{"key":"1448_CR25","doi-asserted-by":"publisher","first-page":"v688","DOI":"10.1093\/annonc\/mdz283.009","volume":"30","author":"N Gaspar","year":"2019","unstructured":"Gaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M. et al. Phase I combination dose-finding\/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to \u2264 25 years with relapsed\/refractory (r\/r) osteosarcoma. Ann. Oncol. 30, v688 (2019).","journal-title":"Ann. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01448-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01448-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T01:02:35Z","timestamp":1653699755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01448-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8,17]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01448-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of each participating institution\u2014Northwestern University, University of Iowa, Mayo Clinic, Medical College of Wisconsin and Washington University School of Medicine. Furthermore, written consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All data are available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research was sponsored by Northwestern University, with limited collaborative support from Novartis Pharmaceuticals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}